NCT01466322 - A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 2010

Primary Completion Date

February 15, 2011

Study Completion Date

February 15, 2011

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state

Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.

Trial Locations (1)

4006

GSK Investigational Site, Herston